Challenges in translating plasma proteomics from bench to bedside: Update from the NHLBI Clinical Proteomics Programs

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 295, Issue 1, 2008, Pages

  Gerszten, Robert E ^a   Accurso, Frank ^b   Bernard, Gordon R ^c   Caprioli, Richard M ^d   Klee, Eric W ^e   Klee, George G ^e   Kullo, Iftikhar ^e   Laguna, Theresa A ^b   Roth, Frederick P ^f   Sabatine, Marc ^g   Srinivas, Pothur ^h   Wang, Thomas J ^a   Ware, Lorraine B ^c,i  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

ⁱ T1218 MCN ^*  (United States)

Author keywords

Protein content; Proteome

Indexed keywords

PROTEOME; BIOLOGICAL MARKER;

ENZYME ACTIVITY; GENOMICS; IMMUNOASSAY; IMMUNOGENICITY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEOMICS; REVIEW; ANIMAL; FACTUAL DATABASE; HUMAN; METABOLISM; PLASMA; SENSITIVITY AND SPECIFICITY;

ANIMALS; BIOLOGICAL MARKERS; DATABASES, FACTUAL; HUMANS; PLASMA; PROTEOME; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

EID: 49049098527     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00044.2008     Document Type: Review

References (51)

1. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 215: 403-410, 1990.
2. Anderson NL, Anderson NG, Haines LR, Hardi DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies. J Proteome Res 3: 235-244, 2004.
3. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3: 311-326, 2004.
4. BD Biosciences. BD Bioscences FACSarray, accessed December 2007 at http://www.bdbiosciences.com/pharmingen/products/display_product.php?keyID=9.
5. Berriz GF, King OD, Bryant B, Sander C, Roth FP. Characterizing gene sets with FuncAssociate. Bioinformatics 19: 2502-2504, 2003.
6. Bio-Rad Laboratories. Bio-Rad Bio-Plex System and Suspension Array Technology, accessed December 2007 at www.biorad.com/bio-plex.
7. Bjorhall K, Miliotis T, Davidsson P. Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 5: 307-317, 2005.
8. Blom N, Gammeltoft S, Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 294: 1351-1362, 1999.
9. Boeckmann B, Bairoch A, Apweiler R, Blatter MC, Estreicher A, Gasteiger E, Martin MJ, Michoud K, O'Donovan C, Phan I, Pilbout S, Schneider M. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res 31: 365-370, 2003.
10. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115: 928-935, 2007.
11. Elia G, Silacci M, Scheurer S, Scheuermann J, Neri D. Affinity-capture reagents for protein arrays. Trends Biotechnol 20: S19-S22, 2002.
12. Endogen. Endogen Searchlight, accessed December 2007 at http://www.endogen.com/services/.
13. Glokler J, Angenendt P. Protein and antibody microarray technology. J Chromatogr B Analyt Technol Biomed Life Sci 797: 229-240, 2003.
14. Granger J, Siddiqui J, Copeland S, Remick D. Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics 5: 4713-4718, 2005.
15. Guo T, Chan M, Soldin SJ. Steroid profiles using liquid chromatography-tandem mass spectrometry with atmospheric pressure photoionization source. Arch Pathol Lab Med 128: 469-475, 2004.
16. Hunsucker SW, Accurso FJ, Duncan MW. Proteomics in pediatric research and practice. Adv Pediatr 54: 9-28, 2007.
17. Jameson BA, Wolf H. The antigenic index: a novel algorithm for predicting antigenic determinants. Comput Appl Biosci 4: 181-186, 1988.
18. Julenius K, Molgaard A, Gupta R, Brunak S. Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites. Glycobiology 15: 153-164, 2005.
19. Kersten B, Wanker EE, Hoheisel JD, Angenendt P. Multiplex approaches in protein microarray technology. Expert Rev Proteomics 2: 499-510, 2005.
20. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 6: 2212-2229, 2007.
21. Kirschenlohr HL, Griffin JL, Clarke SC, Rhydwen R, Grace AA, Schofield PM, Brindle KM, Metcalfe JC. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med 12: 705-710, 2006.
22. Klee GG. Laboratory techniques for recognition of endocrine disorders. In: Williams Textbook of Endocrinology (11th ed.), edited by Kronenberg HM, Melmed S, Polonsky KS, and Larsen PR. Philadelphia, PA: Saunders Elsevier, 2008, p. 67-81.
23. Luminex Corporation. Luminex Corporation xMAP Technology, accessed December 2007 at http://www.luminexcorp.com/index.html.
24. Martosella J, Zolotarjova N, Liu H, Nicol G, Boyes BE. Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. J Proteome Res 4: 1522-1537, 2005.
25. Melton L. Protein arrays: proteomics in multiplex. Nature 429: 101-107, 2004.
26. Meso Scale Discovery. Meso-scale Discoveries Sector Imager, accessed December 2007 at http://www.mesoscale.com/.
27. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273, 2003.
28. Morozov VN, Morozova TY. Active bead-linked immunoassay on protein microarrays. Anal Chim Acta 564: 40-52, 2006.
29. Nielsen EM, Hansen L, Carstensen B, Echwald SM, Drivsholm T, Glumer C, Thorsteinsson B, Borch-Johnsen K, Hansen T, Pedersen O. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 52: 573-577, 2003.
30. Nilsson P, Paavilainen L, Larsson K, Odling J, Sundberg M, Andersson AC, Kampf C, Persson A, Al-Khalili Szigyarto C, Ottosson J, Bjorling E, Hober S, Wernerus H, Wester K, Ponten F, Uhlen M. Towards a human proteome atlas: high-throughput generation of monospecific antibodies for tissue profiling. Proteomics 5: 4327-4337, 2005.
31. Pencina MJ, D'Agostino RBS, D'Agostino RBJ, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172, 2008.
32. Pepe MS, Thompson ML. Combining diagnostic test results to increase accuracy. Biostatistics 1: 123-140, 2000.
33. Pruitt KD, Tatusova T, Maglott DR. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 35: D61-D65, 2007.
34. Qiagen. Qiagen Liquichip, accessed December 2007 at http://www1.qiagen.com/Products/Protein/Assay/LiquiChipSystem/ LiquiChipWorkstation.aspx.
35. Rai AJ, Vitzthum F. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics 3: 409-426, 2006.
36. Raj JU, Aliferis C, Caprioli RM, Cowley AW Jr, Davies PF, Duncan MW, Erle DJ, Erzurum SC, Finn PW, Ischiropoulos H, Kaminski N, Kleeberger SR, Leikauf GD, Loyd JE, Martin TR, Matalon S, Moore JH, Quackenbush J, Sabo-Attwood T, Shapiro SD, Schnitzer JE, Schwartz DA, Schwiebert LM, Sheppard D, Ware LB, Weiss ST, Whitsett JA, Wurfel MM, Matthay MA. Genomics and proteomics of lung disease: conference summary. Am J Physiol Lung Cell Mol Physiol 293: L45-L51, 2007.
37. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24: 971-983, 2006.
38. Safarik I, Safarikova M. Magnetic techniques for the isolation and purification of proteins and peptides. Biomagn Res Technol 2: 7, 2004.
39. Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 4: 406-417, 2007.
40. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100: 9440-9445, 2003.
41. Tavazoie S, Hughes JD, Campbell MJ, Cho RJ, Church GM. Systematic determination of genetic network architecture. Nat Genet 22: 281-285, 1999.
42. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 342: 1301-1308, 2000.
43. US Department of Health and Human Services and Food and Drug Administration Center for Devices. Draft Guidance for Industry, Clinical Laboratories, and FDA Staff. In Vitro Diagnostic Multivariate Index Assays, accessed December 2007 at http://www.fda.gov/cdrh/oivd/guidance/1610.pdf.
44. Villanueva J, Philip J, Chaparro CA, Li Y, Toledo-Crow R, DeNoyer L, Fleisher M, Robbins RJ, Tempst P. Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 4: 1060-1072, 2005.
45. Wang TJ. New cardiovascular risk factors exist, but are they clinically useful? Eur Heart J 29: 441-444, 2008.
46. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355: 2631-2639, 2006.
47. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 355: 2615-2617, 2006.
48. Waterboer T, Sehr P, Pawlita M. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 309: 200-204, 2006.
49. Whiteaker JR, Zhao L, Zhang HY, Feng LC, Piening BD, Anderson L, Paulovich AG. Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem 362: 44-54, 2007.
50. Winfield KR, Gard S, Kent GN, Sly PD, Brennan S. Assay for urinary desmosines in a healthy pre-pubertal population using an improved extraction technique. Ann Clin Biochem 43: 146-152, 2006.
51. Zhu H, Snyder M. Protein chip technology. Curr Opin Chem Biol 7: 55-63, 2003.